INDIANAPOLIS, Aug. 1, 2018 /PRNewswire/ —Â The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, is now available to residents in the U.S. and all U.S. territories. Beginning today, this suite of solutions will provide many options â€“ some being offered for the first time â€“ that can significantly lower and cap high monthly out-of-pocket costs for some people who use Lilly insulins such as HumalogÂ® (insulin lispro) and HumulinÂ® (insulin human injection). Dedicated representatives will review the personal circumstances and identify options for people who pay near the full list price, such as the uninsured and people in the deductible phase of their high-deductible insurance plans, as well as potential solutions for people with lower incomes.
“We don’t want anyone to have to pay full list price for their insulin, and many people who do will be able to pay significantly less by calling our helpline,” said Mike Mason, senior vice president, Connected Care and Insulins. “Our goal is to ensure that people paying high out-of-pocket costs for Lilly insulins are matched with the best solution available to reduce their financial burden and help ensure they receive the treatment they need.”
Help is available at the Lilly Diabetes Solution Center by dialing (833) 808-1234, where people can talk to representatives between the hours of 9 a.m. and 8 p.m. (ET) Monday through Friday. Services will be offered in English, Spanish and several other languages. The helpline offers a range of new solutions for people with the greatest need including point-of-sale savings, information on accessing insulin through free clinics, and support for immediate needs.
Savings will vary based upon the individual circumstances of each person who calls the helpline. For people who already have co-pay or co-insurance plans, or are enrolled in Medicare Part D, the cost at the pharmacy may not change. Based on estimates from market research data, more than 400,000 people living with diabetes in the U.S. and Puerto Rico could benefit from the new solution center. Lilly is promoting the helpline in a variety of ways including through paid advertising, social media and outreach to the diabetes community.
The following solutions are now available through the helpline:
Point of sale savingsÂ
The helpline will use a suite of solutions â€“ including new offerings â€“ to find answers for people who face the highest out-of-pocket costs at the pharmacy such as people who are uninsured and people in the deductible phase of their high-deductible commercial insurance plans. The solutions will be customizable and the amount of the reduction will vary person-to-person based upon their circumstances. The out-of-pocket costs for people who use traditional co-pay or co-insurance plans will continue to be set by their health insurer. Additionally, federal regulations prevent people who use Medicare Part D or other federal programs from obtaining additional point-of-sale savings.
Lilly is donating insulin to three relief agencies â€“ Americares, Direct Relief, and Dispensary of Hope â€“ to eventually supply nearly 150 free clinics across the U.S. with Lilly insulin. Helpline representatives will point people toward clinics that are most convenient to them and provide information about how to obtain insulin at those locations. Lilly is working now with the relief agencies to identify as many clinics as possible that can adequately store and distribute insulin to people who need it. (Qualifications will differ clinic-to-clinic).
Immediate needs for insulinÂ
If someone has an immediate need for insulin, they will be able to call the Lilly Diabetes Solution Center to learn about immediate and longer-term options.
“We encourage people who pay near full list price for insulin and those who don’t have the financial means to afford the costs they face to call the helpline,” Mason said. “We want to help people find ways to obtain insulin at more affordable prices.”
HumalogÂ® is used to treat people with diabetes for the control of blood sugar. HumalogÂ® Mix75/25â„˘ (75% insulin lispro protamine suspension and 25% insulin lispro injection) and HumalogÂ® Mix50/50â„˘ (50% insulin lispro protamine suspension and 50% insulin lispro injection) are used to treat adults with diabetes for the control of high blood sugar.
Do not take Humalog if your blood sugar is too low (hypoglycemia) or if you are allergic to insulin lispro or any of the ingredients in Humalog.
Important Safety Information for Humalog
What is the most important information I should know about Humalog?
Who should not take Humalog?
Before using Humalog, what should I tell my healthcare providers?
How should I use Humalog?
What are the possible side effects of Humalog?
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Humalog is available by prescription only.
Please see Instructions for Use included with the Humalog KwikPen.
HI CON ISI 06JUN2017
About Lilly DiabetesÂ
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutionsâ€”from medicines to support programs and moreâ€”we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes and on Facebook: LillyDiabetesUS.
AboutÂ Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY
HumalogÂ® and KwikPenÂ® are registered trademarks of Eli Lilly and Company.
This press release contains forward-looking statements about the Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, and reflects Lilly’s current beliefs. There is no guarantee that this suite of solutions will significantly lower and cap high monthly out-of-pocket costs for some people who use Lilly insulins. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
#Â Â Â Â Â Â Â Â #Â Â Â Â Â Â Â Â #
PP-DB-US-0541/2018 Â©LillyUSA, LLC 2018. All rights reserved.
Greg Kueterman; [email protected]; (317) 432-5195
Dani Barnhizer ; [email protected]; (317) 607-6119
View original content with multimedia:http://www.prnewswire.com/news-releases/lilly-diabetes-solution-center-now-open-to-help-people-with-insulin-affordability-300689746.html
SOURCE Eli Lilly and Company